Zobrazeno 1 - 10
of 27
pro vyhledávání: ''
Autor:
Dorte Linnemann, Julia S. Johansen, Kristin Skougaard, Dorte Nielsen, Jakob V. Schou, Mette Karen Yilmaz, Per Pfeiffer, Finn Ole Larsen, Benny V. Jensen, Estrid Høgdall, Helle Hjorth Johannesen
Publikováno v:
International Journal of Cancer. 148:2542-2556
Metastatic colorectal cancer (mCRC) is treated with cetuximab 250 mg/m2 administered weekly over 1 hour or biweekly (q2w) over 3.5 hours when combined with irinotecan. This prospective study investigated cetuximab 500 mg/m2 plus irinotecan 180 mg/m2
Autor:
Livio Trusolino, Jochen H. M. Prehn, Steven Carberry, Andreas U. Lindner, Robert O'Byrne, Manuela Salvucci, Mattia Cremona, Ana Barat, Eugenia R. Zanella, Naser Monsefi, Andrea Bertotti, Bryan T. Hennessy
Publikováno v:
International Journal of Cancer. 147:2891-2901
Antibodies targeting the human epidermal growth factor receptor (EGFR) are used for the treatment of RAS wild-type metastatic colorectal cancer. A significant proportion of patients remains unresponsive to this therapy. Here, we performed a reverse p
Autor:
Henning Willers, Zofia Kryzmien, Meng Wang, Michael H. Baumann, Cyril H. Benes, Sandra Hering, Mechthild Krause, Kristin Gurtner, Lydia Koi
Publikováno v:
Int J Cancer
International Journal of Cancer 147(2020)2, 472-477
International Journal of Cancer 147(2020)2, 472-477
Recent clinical data have linked KRAS/TP53 co-mutation (mut) to resistance to radiotherapy (RT), but supporting laboratory in vivo evidence is lacking. In addition, the ability of different radiation doses, with/without epidermal growth factor recept
Autor:
Francesco Sclafani, Susana Roselló, Sanna Hulkki Wilson, David Cunningham, David Gonzalez de Castro, Gina Brown, Andrew Wotherspoon, Ian Chau, Janet Thomas, Ruwaida Begum, Jacqui Oates, Bengt Glimelius, Daina Tait, Jaume Capdevila, Eleftheria Kalaitzaki
Publikováno v:
International Journal of Cancer. 146:94-102
Little information is available on the clinical significance of cancer-related genes such as KRAS, NRAS, BRAF, PIK3CA and TP53 in nonmetastatic rectal cancer. We investigated mutations of these genes in a large prospective series of locally advanced
Autor:
Aron Popovtzer, Manu Prasad, Jonathan Zorea, José Baselga, Limor Cohen, Raphael Pelossof, Matthew G. Fury, Fabiola Cecchi, Ben-Zion Joshua, Liz Cohen, Ofra Novoplansky, Nora Katabi, Maurizio Scaltriti, Ksenia M. Yegodayev, Moshe Elkabets
Publikováno v:
International Journal of Cancer. 145:748-762
An understanding of the mechanisms underlying acquired resistance to cetuximab is urgently needed to improve cetuximab efficacy in patients with head and neck squamous cell carcinoma (HNSCC). Here, we present a clinical observation that MET pathway a
Autor:
Lin Wang, Jinjun Rao, Na Huang, Zhenzhen Wu, Hongxiang Huang, Yang Li, Jianping Bin, Wangjun Liao, Huanrong Ma, Yulin Liao, Jianjun Peng, Yi Liao, Li Sun, Minyu Zhou, Min Shi
Publikováno v:
International Journal of Cancer. 142:2578-2588
Cetuximab resistance is a key barrier in treating metastatic colorectal cancer (mCRC). Targeting of metabolic resources import could resensitize drug-resistant cancer cells to anticancer treatments. Here we showed that the expression of the glutamine
Autor:
Yunhong Tian, Guoqian Zhang, Ronghui Zheng, Weijun Zhang, Jie Lin, Yunming Tian, Xing Zeng, Yawei Yuan
Publikováno v:
International Journal of Cancer. 142:2198-2206
Agents targeting epidermal growth factor receptor (EGFR) are used to treat head and neck squamous cell carcinoma (HNSCC); however, their efficacy and safety is poorly understood. Here we evaluated the efficacy and safety of anti-EGFR agents administe
Autor:
Markus Moehler, Frank Kullmann, Jobst C. von Einem, Salah-Eddin Al-Batran, Sebastian Müller, Lisa Miller-Phillips, Thomas Kirchner, Julian Walter Holch, Volker Heinemann, Andreas Jung, Thomas Decker, Hartmut Link, Andreas Rost, Michael Scholz, Alexander Kiani, Werner Scheithauer, Tobias Heintges, Christian A. Lerchenmuller, Dominik Paul Modest, Heinz-Gert Höffkes, Ursula Vehling-Kaiser, Sebastian Stintzing, Ludwig Fischer von Weikersthal, Ingrid Ricard, Reinhard Udo Lindig, Christoph Kahl
Publikováno v:
International Journal of Cancer. 142:1047-1055
In metastatic colorectal cancer (mCRC), liver-limited disease (LLD) is associated with a higher chance of metastectomy leading to long-term survival. However, limited data describes the prognostic and predictive relevance of initially unresectable LL
Autor:
Michael J. Hayman, Edward L. Chan, James Keller, Jens Hoffmann, Konrad Klinghammer, Jonathan George
Publikováno v:
International Journal of Cancer. 142:156-164
Tyrosine kinase inhibitors are effective treatments for cancers. Knowing the specific kinase mutants that drive the underlying cancers predict therapeutic response to these inhibitors. Thus, the current protocol for personalized cancer therapy involv
Autor:
Ling Guo, Ka Jia Cao, Hao Yuan Mo, Qi Yang, Tao Yu, Jibin Li, Chao Nan Qian, Yi Nuan Zhang, Xiong Zou, Jing Yu Cao, Rou Jiang, Chaofeng Li, Yi Jun Hua, You Ping Liu, Rui Sun, Ying Sun, Ai Hua Lin, Jun Ma, Ming Yuan Chen, Rui You, Meng Xia Zhang
Publikováno v:
International Journal of Cancer. 141:1265-1276
To compare intensity-modulated radiotherapy (IMRT) with cisplatin (CDDP) versus cetuximab (CTX) and nimotuzumab (NTZ) for Stage II-IVb Nasopharyngeal Carcinoma (NPC). A total of 1,837 patients with stage II - IVb NPC who received IMRT plus CTX or NTZ